Congenital heart block: identification of autoantibody binding site on the extracellular loop (domain I, S5-S6) of alpha(1D) L-type Ca channel.
Congenital heart block (CHB) is an autoimmune disease associated with autoantibodies against intracellular ribonucleoproteins SSB/La and SSA/Ro. The hallmark of CHB is complete atrioventricular block. We have recently established that anti-SSA/Ro -SSB/La autoantibodies inhibit alpha(1D) L-type Ca current, I(Ca-L), and cross-react with the alpha(1D) Ca channel protein. This study aims at identifying the possible binding sites on alpha(1D) protein for autoantibodies from sera of mothers with CHB children. GST fusion proteins of the extracellular regions between the transmembrane segments (S5-S6) of each of the four alpha(1D) Ca channel protein domains I-IV were prepared and tested for reactivity with sera from mothers with CHB children and controls using ELISA. Sera containing anti-Ro/La autoantibodies from 118 mothers with CHB children and from 15 mothers with anti-Ro/La autoantibodies but have healthy children, and from 28 healthy mothers without anti-Ro/La autoantibodies and healthy children were evaluated. Seventeen of 118 (14.4%) sera from mothers with CHB children reacted with the extracellular loop of domain I S5-S6 region (E1). In contrast, only 2 of 28 (7%) of sera from healthy mothers (-anti-Ro/La) and healthy children reacted with E1 loop and none (0 of 15) of sera from healthy mothers (+anti-Ro/La) and healthy children reacted with the E1 loop. Preincubation of E1 loop with the positive sera decreased the O.D reading establishing the specificity of the response. Electrophysiological characterization of the ELISA positive sera and purified IgG showed inhibition (44.1% and 49.8%, respectively) of the alpha(1D) I(Ca-L) expressed in tsA201 cells. The inhibition was abolished when the sera were pre-incubated with E1 fusion protein. The results identified the extracellular loop of domain I S5-S6 of L-type Ca channel alpha(1D) subunit as a target for autoantibodies from a subset of mothers with CHB children. This novel finding provides insights into the potential development of therapeutic peptides that could bind to the pathogenic antibodies and prevent CHB.
Karnabi
Eddy
E
Molecular and Cellular Cardiology Program, VA New York Harbor Healthcare System and SUNY Downstate Medical Center, Brooklyn, NY 11209, USA.
Qu
Yongxia
Y
Wadgaonkar
Raj
R
Mancarella
Salvatore
S
Yue
Yuankun
Y
Chahine
Mohamed
M
Clancy
Robert M
RM
Buyon
Jill P
JP
Boutjdir
Mohamed
M
D001323:Autoantibodies / Q000097:blood / Q000494:pharmacology*; D001324:Autoantigens / Q000276:immunology; D002121:Calcium Channel Blockers / Q000097:blood / Q000494:pharmacology*; D020746:Calcium Channels, L-Type / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D015195:Drug Design; D018604:Epitope Mapping; D005260:Female; D006327:Heart Block / Q000097:blood / Q000151:congenital / Q000276:immunology* / Q000517:prevention & control; D006801:Humans; D011247:Pregnancy; D011487:Protein Conformation; D015202:Protein Engineering; D017434:Protein Structure, Tertiary / Q000235:genetics; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D012261:Ribonucleoproteins / Q000276:immunology; D000097585:SS-B Antigen; D000099207:SS-A Antigen
D001323:Autoantibodies; D001324:Autoantigens; D002121:Calcium Channel Blockers; D020746:Calcium Channels, L-Type; D011993:Recombinant Fusion Proteins; D012261:Ribonucleoproteins; D000097585:SS-B Antigen; D000099207:SS-A Antigen